Business Wire

Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer

Share

Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, today announced that it has expanded its CE mark of the QuantideX® qPCR BCR-ABL IS Kit and QuantideX® qPCR BCR-ABL minor Kit to include clinical use on the Roche Diagnostics cobas z 480 Analyzer. The exquisite sensitivity and precision of the assays support clinicians in the rapidly evolving European clinical practice of therapy cessation for long-term responders on tyrosine kinase inhibitor (TKI) therapies. The available platforms, which also include the Applied Biosystems® 7500 Fast Dx Real-Time PCR instrument, improve the reach of the portfolio in Europe and Latin America.

“As a global solutions provider, we are committed to ensuring that our best-in-class CML monitoring assays are widely available to deliver powerful answers that can impact patient decisions,” said Matthew McManus, M.D., Ph.D., president and chief executive officer of Asuragen. “Making our BCR-ABL portfolio compatible with the 7500 Fast Dx and cobas z 480 platforms will help ensure that we can serve even more patients around the world.”

About the QuantideX ® qPCR BCR-ABL Portfolio

The QuantideX® qPCR BCR-ABL portfolio provides laboratories with robust, reliable and comprehensive solutions to accurately and sensitively monitor patients with chronic myeloid leukemia (CML) on TKI therapy. The portfolio includes:

  • QuantideX® qPCR BCR-ABL IS Kit -- for detecting and quantifying major (e13a2, e14a2) BCR-ABL1 fusion transcripts. Its software objectively and automatically reports results on the International Scale via a four-point calibrator system, while the CE marked product also features ABL copy number reporting to ensure alignment to European consensus guidelines. It is also cleared by the U.S. Food and Drug Administration for monitoring BCR-ABL levels in CML patients irrespective of TKI therapy or disease management approach.
  • QuantideX® qPCR BCR-ABL minor Kit -– for detecting and quantifying minor (e1a2) BCR-ABL1 fusion transcripts. Results are reported automatically as both BCR-ABL1/ABL ratio and ABL copy number. It is CE marked for U.S. export only.

Key benefits of the assays include unsurpassed sensitivity to better assess clinical response, rapid time-to-result with minimal hands-on-time, multiplexed assay design to enable throughput of up to 49 samples, and Armored RNA®-based standards that provide accurate RNA quantification. The QuantideX® qPCR BCR-ABL IS and minor kits offer validated clinical sensitivities that detect residual amounts of disease down to 0.002% IS (MR4.7 LOD) and 0.0025% ratio (LR4.61), respectively, both determined using clinically representative samples, not human-derived cell lines. The simple, streamlined and common workflow of both kits facilitates high ease of implementation and empowers laboratories of all sizes to offer high quality, routine BCR-ABL testing. The kits have been validated in thousands of clinical specimens and together provide significant coverage of major and minor breakpoints.

About Asuragen

Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Asuragen, Inc.
Lynne Hohlfeld, 512-681-5200
SVP, Corporate Development and CFO
lhohlfeld@asuragen.com
or
W2O pure
Media:
Kelly Boothe, 415-946-1076
kboothe@w2ogroup.com
or
Investors:
Courtney Dugan, 212-257-6723
cdugan@w2ogroup.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PAN Finance Names Libertex ‘Global CFD Broker of the Year’29.3.2024 06:25:00 CET | Press release

As the first quarter of 2024 draws to a close, Libertex is thrilled to announce its first accolade of the new year! The established global financial publication PAN Finance has determined Libertex to be the ‘CFD Broker of the Year – Global 2024’ following a rigorous evaluation process conducted by the publication's highly experienced editorial and research teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328235325/en/ (Graphic: Libertex) PAN Finance is a trusted source of global financial intelligence with an impressively wide readership across 150 countries. Its ecosystem includes a quarterly magazine, special reports, a news website, and various social media channels. As an organisation, PAN Finance is committed to providing concise, intelligent, and up-to-date news for a worldwide readership of specialists spanning the entire finance industry. The company's awards programme aims to serve as a true indicator of exc

Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.29.3.2024 02:39:00 CET | Press release

Midea Group: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328526418/en/ Background: Midea Group, a leading global technology group, recently released its 2023 Environmental, Social, and Governance (ESG) Report with ambitious sustainable development goals set for 2030. They include achieving over 500 megawatts of photovoltaic power generation, reducing greenhouse gas emission intensity (scopes 1 and 2) by 0.040, secure Energy Management System Certification for 50 factories, and achieve 100% carbon footprint accounting for major categories of smart home appliances. This is aligned with the Sustainable Development Report Standards of the Global Report Standards of the Global Reporting Initiative (GRI). The new report and campaign focuses on four dimensions: Protect the Blue Planet, Build a Harmonious Community, Practice 'Bring Great Innovations to Life', and Jointly Create the Prosperous Ecology. The campaign: Midea’s ESG

DC Secretary Announces Annual Determinations Committees Outcome28.3.2024 21:14:00 CET | Press release

DC Administration Services, Inc. has today announced the composition of five regional Determinations Committees (DCs), effective from April 27, 2024. Voting Dealers (for all regions): Voting Non-Dealers (for all regions): Bank of America N.A. Citadel LLC Barclays Bank plc Elliott Management Corporation BNP Paribas Pacific Investment Management Company LLC Citibank, N.A. Deutsche Bank AG Goldman Sachs International JPMorgan Chase Bank, N.A. Voting Dealer for the Americas, EMEA, AEJ, and Japan Determination Committees: Mizuho Securities Co., Ltd. The process for selecting DC members is specified in the DC rules. The DC rules, along with more information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommittees.org/. View source version on businesswire.com: https://www.businesswire.com/news/home/20240328441002/en/Contact information Press Inquiries: Orlando Figueroa orlando.figueroa@citadelspv.com

LambdaTest Launches The Phoenix Project, an Employee Resource Group for Women28.3.2024 16:00:00 CET | Press release

LambdaTest, a leading cloud-based unified testing platform, announced the launch of The Phoenix Project, an Employee Resource Group (ERG) dedicated to supporting and promoting the success of its female employees. “LambdaTest is committed to fostering a diverse, inclusive, and equitable workplace where all employees feel valued and empowered to reach their full potential,” said Chandini Chopra, VP of People and Culture at LambdaTest. “The Phoenix Project is a critical step towards achieving this goal by providing a platform for professional development, networking, and mentorship, especially for our women employees.” The Phoenix Project Aims To: Offer professional development workshops, networking opportunities, and dedicated time off for women to participate in ERG initiatives. Provide mentorship programs connecting senior female employees with mentees. Promote leadership development among women within the company. Create a sense of community for women in the workplace. Leadership and

The reopening of the Yokohama Museum of Art adds another innovative and distinctive venue for events in Yokohama28.3.2024 16:00:00 CET | Press release

After extensive renovations, the iconic Yokohama Museum of Art has reopened its doors to visitors from all over the world. The museum’s reopening paves the way to new and closer collaboration with international events in Yokohama. This extraordinary venue is the ideal setting for a one-of-a-kind gathering, in part, supported by the Yokohama Convention & Visitors Bureau (hereinafter YCVB). The Yokohama Museum of Art Founded in 1989, the Yokohama Museum of Art collects over 14,000 works of art that reflect the many facets of life in Yokohama—past, present, and future. The reopening of the museum coincides with the Yokohama Triennale, an international exhibition featuring contemporary artists whose decentralized exhibits turn the entire metropolis into an art museum. The 8th Yokohama Triennale is being held from March 15 to June 9, 2024, with the Yokohama Museum of Art being a pivotal venue for the exhibition. With the museum firmly back on the map as Yokohama’s leading artistic venue, YC

HiddenA line styled icon from Orion Icon Library.Eye